Kodama-XUUB: an Informative Classification for Alveolar Echinococcosis Hepatic Lesions on Magnetic Resonance Imaging

Overview

Journal Parasite

Specialty Parasitology

Date 2021 Sep 27

PMID 34569927

Citations 6

Authors

Eleonore Brumpt

Wenya Liu

Tilmann Graeter

Paul Calame

Shi Rong

Yi Jiang

Weixia Li

Haihua Bao

Eric Delabrousse

Affiliations

Soon will be listed here.

Abstract

Objective: To propose a modification of the Kodama classification to classify type III lesions of alveolar echinococcosis (AE) that do not have microcysts.

Materials And Methods: 200 magnetic resonance imaging (MRI) images of AE liver lesions from four endemic regions of the world were classified according to Kodama, distinguishing within type III those with microcysts from those without. Each center included 50 MRIs of patients with unoperated AA liver lesions. The first 50 cases were classified by a first reader in the presence of four second-line readers from each region. Then each second-line reader classified his or her 50 cases.

Results: In all centers, type III lesions were predominant: 58% of the total lesions and 23% of them were without microcysts. The average age of the patients was 47 years. In China, the patients were on average younger and the lesions larger. German patients had more lesions within the liver. Type I and II lesions, synonymous with earlier diagnosis, were more common in Europe.

Conclusion: The Kodama classification needed to be modified because of the existence of a significant proportion of unclassifiable lesions. This is especially true since the presence of microcysts is an informative element of parasite activity. Therefore, this study proposes a Kodama-XUUB classification with type IIIa lesions having microcysts and type IIIb lesions not having microcysts.

Citing Articles

Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.

Liu H, Xie Y, An X, Xu D, Cai S, Chu C Diagnostics (Basel). 2025; 15(5).

PMID: 40075832 PMC: 11898896. DOI: 10.3390/diagnostics15050585.

Correlation between imaging features and rEm18 antibodies in alveolar echinococcosis: results from a multicenter study in France.

Simon G, Grenouillet F, Richou C, Delabrousse E, Blagoskonov O, Minello A Parasite. 2025; 32:8.

PMID: 39918234 PMC: 11804184. DOI: 10.1051/parasite/2024076.

A Case Series and Literature Review of Alveolar Echinococcosis in Kashmir, India: An Emerging Endemic Zone for .

Khuroo M, Khuroo N, Rather A Life (Basel). 2024; 14(7).

PMID: 39063549 PMC: 11277966. DOI: 10.3390/life14070794.

Bacterial Infection of an Alveolar Echinococcus Cyst from Septicemia: A Case Report and Review of the Literature.

Buttenschoen J, Pavel V, Mehrl A, Michels B, Albaladejo Fuertes S, Seydel B Medicina (Kaunas). 2023; 59(10).

PMID: 37893546 PMC: 10608314. DOI: 10.3390/medicina59101828.

Circulating Small RNA Profiling of Patients with Alveolar and Cystic Echinococcosis.

Cucher M, Mariconti M, Manciulli T, Vola A, Rosenzvit M, Brehm K Biology (Basel). 2023; 12(5).

PMID: 37237528 PMC: 10215812. DOI: 10.3390/biology12050715.

References

Junghanss T, Menezes da Silva A, Horton J, Chiodini P, Brunetti E . Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg. 2008; 79(3):301-11. View

Kodama Y, Fujita N, Shimizu T, Endo H, Nambu T, Sato N . Alveolar echinococcosis: MR findings in the liver. Radiology. 2003; 228(1):172-7. DOI: 10.1148/radiol.2281020323. View

Vuitton D, Azizi A, Richou C, Vuitton L, Blagosklonov O, Delabrousse E . Current interventional strategy for the treatment of hepatic alveolar echinococcosis. Expert Rev Anti Infect Ther. 2016; 14(12):1179-1194. DOI: 10.1080/14787210.2016.1240030. View

Brunetti E, Kern P, Vuitton D . Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16. DOI: 10.1016/j.actatropica.2009.11.001. View

Aji T, Dong J, Shao Y, Zhao J, Li T, Tuxun T . Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis. J Hepatol. 2018; 69(5):1037-1046. DOI: 10.1016/j.jhep.2018.07.006. View

Wen H, Vuitton L, Tuxun T, Li J, Vuitton D, Zhang W . Echinococcosis: Advances in the 21st Century. Clin Microbiol Rev. 2019; 32(2). PMC: 6431127. DOI: 10.1128/CMR.00075-18. View

Vuitton D, Bresson-Hadni S, Giraudoux P, Bartholomot B, Laplante J, Delabrousse E . [Alveolar echinococcosis: from an incurable rural disease to a controlled urban infection]. Presse Med. 2009; 39(2):216-30. DOI: 10.1016/j.lpm.2008.10.028. View

Torgerson P, Keller K, Magnotta M, Ragland N . The global burden of alveolar echinococcosis. PLoS Negl Trop Dis. 2010; 4(6):e722. PMC: 2889826. DOI: 10.1371/journal.pntd.0000722. View

Torgerson P, Schweiger A, Deplazes P, Pohar M, Reichen J, Ammann R . Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol. 2008; 49(1):72-7. DOI: 10.1016/j.jhep.2008.03.023. View

10.

Piarroux M, Piarroux R, Giorgi R, Knapp J, Bardonnet K, Sudre B . Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients. J Hepatol. 2011; 55(5):1025-33. DOI: 10.1016/j.jhep.2011.02.018. View

11.

Deplazes P, Rinaldi L, Alvarez Rojas C, Torgerson P, Harandi M, Romig T . Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017; 95:315-493. DOI: 10.1016/bs.apar.2016.11.001. View

12.

Bartholomot G, Vuitton D, Harraga S, Shi D, Giraudoux P, Barnish G . Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China. Am J Trop Med Hyg. 2002; 66(1):23-9. DOI: 10.4269/ajtmh.2002.66.23. View

13.

Torgerson P . The emergence of echinococcosis in central Asia. Parasitology. 2013; 140(13):1667-73. DOI: 10.1017/S0031182013000516. View

14.

Stettler M, Rossignol J, Fink R, Walker M, Gottstein B, Merli M . Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol. 2004; 34(5):615-24. DOI: 10.1016/j.ijpara.2004.01.006. View

15.

Zhang C, Shao Y, Yang S, Bi X, Wang H, Yang N . T-cell tolerance and exhaustion in the clearance of Echinococcus multilocularis: role of inoculum size in a quantitative hepatic experimental model. Sci Rep. 2017; 7(1):11153. PMC: 5593833. DOI: 10.1038/s41598-017-11703-1. View

16.

Graeter T, Kratzer W, Oeztuerk S, Haenle M, Mason R, Hillenbrand A . Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World J Gastroenterol. 2016; 22(13):3621-31. PMC: 4814648. DOI: 10.3748/wjg.v22.i13.3621. View

17.

Caoduro C, Porot C, Vuitton D, Bresson-Hadni S, Grenouillet F, Richou C . The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. J Nucl Med. 2013; 54(3):358-63. DOI: 10.2967/jnumed.112.109942. View

18.

Siles-Lucas M, Merli M, Mackenstedt U, Gottstein B . The Echinococcus multilocularis 14-3-3 protein protects mice against primary but not secondary alveolar echinococcosis. Vaccine. 2003; 21(5-6):431-9. DOI: 10.1016/s0264-410x(02)00517-0. View

19.

Brenner D, Hall E . Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007; 357(22):2277-84. DOI: 10.1056/NEJMra072149. View

20.

Brumpt E, Blagosklonov O, Calame P, Bresson-Hadni S, Vuitton D, Delabrousse E . AE hepatic lesions: correlation between calcifications at CT and FDG-PET/CT metabolic activity. Infection. 2019; 47(6):955-960. DOI: 10.1007/s15010-019-01328-z. View